Skip to main content
Skip to page content
Skip Navigation LinksPennsylvania Department of Health > My Health > School Health > Narcan Program in Schools

naloxone program for schools

Private/nonpublic schools that house grades 9-12 are now eligible to receive Narcan.

Prior to submitting an application for the free two-dose carton of Adapt Pharma Narcan, be sure to review the application packet (see link to the top right of the screen) for specific information on required trainings and development of policies and standing orders.

The free Narcan doses, distributed to schools by the Department of Health, will expire May 31, 2018.  This was a one-time offer from Adapt Pharma through a grant awarded to Adapt Pharma by the Clinton Foundation.  

There are currently no plans to offer replacement doses.

To order replacement or additional doses of Narcan:

Adapt Pharma has provided the following information if Pennsylvania schools wish to order additional doses of Narcan at a reduced cost. The below information is for both existing and new schools who wish to purchase additional or replacement doses of Narcan.

Direct Purchasers
Direct purchasers, such as EMS, law enforcement and community-based naloxone distribution programs, can complete the Direct Purchase Intake Form and be contacted by an Adapt Customer Service Representative.Schools qualify as Direct Purchasers:


New Customers

  1. Download and complete the form above. If you have any questions, please call Adapt Customer Service at 1-844-4-NARCAN (844) 462-7226
  2. Fax or email the completed form to Adapt Customer Service at (484) 367-7815 or
  3. A customer service representative will contact you via phone within 24 hours to let you know your documentation has been sent and is awaiting approval


Administration of Narcan (naloxone) - The departments of Health, Education and Drug and Alcohol Programs sent a PENN*LINK to school administrators in September encouraging schools to consider establishing a naloxone program. It is recommended that schools make this determination using a team approach, consisting of the administration, solicitor, doctor and nurse(s).
Additional Resources 
As of November 19, 2015, the FDA has approved the Adapt Pharma intranasal formulation of naloxone. Access the press release here. 
Updated: January 2018